ID   CP17A_HUMAN             Reviewed;         508 AA.
AC   P05093; Q5TZV7;
DT   13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT   13-AUG-1987, sequence version 1.
DT   10-MAY-2017, entry version 196.
DE   RecName: Full=Steroid 17-alpha-hydroxylase/17,20 lyase;
DE            EC=1.14.14.19 {ECO:0000269|PubMed:22266943};
DE   AltName: Full=17-alpha-hydroxyprogesterone aldolase;
DE            EC=1.14.14.32 {ECO:0000269|PubMed:22266943};
DE   AltName: Full=CYPXVII;
DE   AltName: Full=Cytochrome P450 17A1;
DE   AltName: Full=Cytochrome P450-C17;
DE            Short=Cytochrome P450c17;
DE   AltName: Full=Steroid 17-alpha-monooxygenase;
GN   Name=CYP17A1; Synonyms=CYP17, S17AH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3025870; DOI=10.1073/pnas.84.2.407;
RA   Chung B.-C., Picado-Leonard J., Haniu M., Bienkowski M., Hall P.F.,
RA   Shively J.E., Miller W.L.;
RT   "Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase):
RT   cloning of human adrenal and testis cDNAs indicates the same gene is
RT   expressed in both tissues.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:407-411(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3500022; DOI=10.1089/dna.1987.6.439;
RA   Picado-Leonard J., Miller W.L.;
RT   "Cloning and sequence of the human gene for P450c17 (steroid 17 alpha-
RT   hydroxylase/17,20 lyase): similarity with the gene for P450c21.";
RL   DNA 6:439-448(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3274893; DOI=10.1210/mend-1-5-348;
RA   Bradshaw K.D., Waterman M.R., Couch R.T., Simpson E.R., Zuber M.X.;
RT   "Characterization of complementary deoxyribonucleic acid for human
RT   adrenocortical 17 alpha-hydroxylase: a probe for analysis of 17 alpha-
RT   hydroxylase deficiency.";
RL   Mol. Endocrinol. 1:348-354(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1964490; DOI=10.1210/mend-4-12-1972;
RA   Brentano S.T., Picado-Leonard J., Mellon S.H., Moore C.C.,
RA   Miller W.L.;
RT   "Tissue-specific, cyclic adenosine 3',5'-monophosphate-induced, and
RT   phorbol ester-repressed transcription from the human P450c17 promoter
RT   in mouse cells.";
RL   Mol. Endocrinol. 4:1972-1979(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2843762; DOI=10.1210/mend-2-6-564;
RA   Kagimoto M., Winter J.S.D., Kagimoto K., Simpson E.R., Waterman M.R.;
RT   "Structural characterization of normal and mutant human steroid 17
RT   alpha-hydroxylase genes: molecular basis of one example of combined 17
RT   alpha-hydroxylase/17,20 lyase deficiency.";
RL   Mol. Endocrinol. 2:564-570(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   3D-STRUCTURE MODELING OF 48-501.
RX   PubMed=10406467; DOI=10.1210/mend.13.7.0326;
RA   Auchus R.J., Miller W.L.;
RT   "Molecular modeling of human P450c17 (17alpha-hydroxylase/17,20-
RT   lyase): insights into reaction mechanisms and effects of mutations.";
RL   Mol. Endocrinol. 13:1169-1182(1999).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 24-508 IN COMPLEXES WITH
RP   HEME; ABIRATERONE AND TOK-001, FUNCTION, CATALYTIC ACTIVITY, AND
RP   COFACTOR.
RX   PubMed=22266943; DOI=10.1038/nature10743;
RA   DeVore N.M., Scott E.E.;
RT   "Structures of cytochrome P450 17A1 with prostate cancer drugs
RT   abiraterone and TOK-001.";
RL   Nature 482:116-119(2012).
RN   [11]
RP   VARIANT AH5 PHE-53 DEL.
RX   PubMed=2808364;
RA   Yanase T., Kagimoto M., Suzuki S., Hashiba K., Simpson E.R.,
RA   Waterman M.R.;
RT   "Deletion of a phenylalanine in the N-terminal region of human
RT   cytochrome P-450(17 alpha) results in partial combined 17 alpha-
RT   hydroxylase/17,20-lyase deficiency.";
RL   J. Biol. Chem. 264:18076-18082(1989).
RN   [12]
RP   VARIANT AH5 PRO-106.
RX   PubMed=1714904;
RA   Lin D., Harikrishna J.A., Moore C.C.D., Jones K.L., Miller W.L.;
RT   "Missense mutation serine106-->proline causes 17 alpha-hydroxylase
RT   deficiency.";
RL   J. Biol. Chem. 266:15992-15998(1991).
RN   [13]
RP   VARIANT AH5 CYS-496.
RX   PubMed=1515452; DOI=10.1016/0925-4439(92)90100-2;
RA   Yanase T., Waterman M.R., Zachmann M., Winter J.S.D., Kagimoto M.;
RT   "Molecular basis of apparent isolated 17,20-lyase deficiency: compound
RT   heterozygous mutations in the C-terminal region (Arg(496)-->Cys,
RT   Gln(461)-->Stop) actually cause combined 17 alpha-hydroxylase/17,20-
RT   lyase deficiency.";
RL   Biochim. Biophys. Acta 1139:275-279(1992).
RN   [14]
RP   VARIANT AH5 THR-342.
RX   PubMed=1740503; DOI=10.1210/jcem.74.3.1740503;
RA   Ahlgren R., Yanase T., Simpson E.R., Winter J.S.D., Waterman M.R.;
RT   "Compound heterozygous mutations (Arg 239-->Stop, Pro 342-->Thr) in
RT   the CYP17 (P45017 alpha) gene lead to ambiguous external genitalia in
RT   a male patient with partial combined 17 alpha-hydroxylase/17,20-lyase
RT   deficiency.";
RL   J. Clin. Endocrinol. Metab. 74:667-672(1992).
RN   [15]
RP   VARIANTS AH5 SER-64 AND ILE-112 INS.
RX   PubMed=8396144;
RA   Imai T., Globerman H., Gertner J.M., Kagawa N., Waterman M.R.;
RT   "Expression and purification of functional human 17 alpha-
RT   hydroxylase/17,20-lyase (P450c17) in Escherichia coli. Use of this
RT   system for study of a novel form of combined 17 alpha-
RT   hydroxylase/17,20-lyase deficiency.";
RL   J. Biol. Chem. 268:19681-19689(1993).
RN   [16]
RP   VARIANT AH5 LEU-373.
RX   PubMed=8245018;
RA   Monno S., Ogawa H., Date T., Fujioka M., Miller W.L., Kobayashi M.;
RT   "Mutation of histidine 373 to leucine in cytochrome P450c17 causes 17
RT   alpha-hydroxylase deficiency.";
RL   J. Biol. Chem. 268:25811-25817(1993).
RN   [17]
RP   VARIANT AH5 487-ASP--PHE-489 DEL.
RX   PubMed=8345056; DOI=10.1210/jcem.77.2.8345056;
RA   Fardella C.E., Zhang L.H., Mahacholklertwattana P., Lin D.,
RA   Miller W.L.;
RT   "Deletion of amino acids Asp487-Ser488-Phe489 in human cytochrome
RT   P450c17 causes severe 17 alpha-hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 77:489-493(1993).
RN   [18]
RP   VARIANT AH5 HIS-440.
RX   PubMed=8027220; DOI=10.1210/jcem.79.1.8027220;
RA   Fardella C.E., Hum D.W., Homoki J., Miller W.L.;
RT   "Point mutation of Arg440 to His in cytochrome P450c17 causes severe
RT   17 alpha-hydroxylase deficiency.";
RL   J. Clin. Endocrinol. Metab. 79:160-164(1994).
RN   [19]
RP   VARIANT AH5 TRP-96.
RX   PubMed=8550762; DOI=10.1210/jcem.81.1.8550762;
RA   Laflamme N., Leblanc J.-F., Mailloux J., Faure N., Labrie F.,
RA   Simard J.;
RT   "Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-
RT   hydroxylase/17-20-lyase deficiency in two French Canadian patients.";
RL   J. Clin. Endocrinol. Metab. 81:264-268(1996).
RN   [20]
RP   VARIANTS AH5 HIS-347 AND GLN-358.
RA   Geller D.H., Mendonca B.B., Miller W.L.;
RT   "The molecular basis of isolated 17,20 lyase deficiency.";
RL   Pediatr. Res. 39:89A-89A(1996).
RN   [21]
RP   VARIANTS AH5 LEU-35; PHE-53 DEL; TRP-96; ASP-177; GLU-330 DEL; CYS-417
RP   AND HIS-496, AND PHOSPHORYLATION.
RX   PubMed=10720067; DOI=10.1210/jcem.85.3.6475;
RA   Biason-Lauber A., Kempken B., Werder E., Forest M.G., Einaudi S.,
RA   Ranke M.B., Matsuo N., Brunelli V., Schoenle E.J., Zachmann M.;
RT   "17alpha-hydroxylase/17,20-lyase deficiency as a model to study
RT   enzymatic activity regulation: role of phosphorylation.";
RL   J. Clin. Endocrinol. Metab. 85:1226-1231(2000).
RN   [22]
RP   VARIANTS AH5 HIS-347; GLN-358 AND CYS-417.
RX   PubMed=11549685; DOI=10.1210/jcem.86.9.7812;
RA   Gupta M.K., Geller D.H., Auchus R.J.;
RT   "Pitfalls in characterizing P450c17 mutations associated with isolated
RT   17,20-lyase deficiency.";
RL   J. Clin. Endocrinol. Metab. 86:4416-4423(2001).
RN   [23]
RP   VARIANT AH5 CYS-93.
RX   PubMed=11836339; DOI=10.1210/jc.87.2.898;
RA   Di Cerbo A., Biason-Lauber A., Savino M., Piemontese M.R.,
RA   Di Giorgio A., Perona M., Savoia A.;
RT   "Combined 17alpha-hydroxylase/17,20-lyase deficiency caused by
RT   Phe93Cys mutation in the CYP17 gene.";
RL   J. Clin. Endocrinol. Metab. 87:898-905(2002).
RN   [24]
RP   VARIANTS AH5 VAL-114; VAL-116; CYS-347 AND HIS-347.
RX   PubMed=12466376; DOI=10.1210/jc.2001-011880;
RA   Van Den Akker E.L.T., Koper J.W., Boehmer A.L.M., Themmen A.P.N.,
RA   Verhoef-Post M., Timmerman M.A., Otten B.J., Drop S.L.S.,
RA   De Jong F.H.;
RT   "Differential inhibition of 17alpha-hydroxylase and 17,20-lyase
RT   activities by three novel missense CYP17 mutations identified in
RT   patients with P450c17 deficiency.";
RL   J. Clin. Endocrinol. Metab. 87:5714-5721(2002).
RN   [25]
RP   VARIANTS AH5 TRP-96; ASP-329; CYS-362; ARG-406 AND LEU-428.
RX   PubMed=14671162; DOI=10.1210/jc.2003-030988;
RA   Martin R.M., Lin C.J., Costa E.M.F., de Oliveira M.L., Carrilho A.,
RA   Villar H., Longui C.A., Mendonca B.B.;
RT   "P450c17 deficiency in Brazilian patients: biochemical diagnosis
RT   through progesterone levels confirmed by CYP17 genotyping.";
RL   J. Clin. Endocrinol. Metab. 88:5739-5746(2003).
RN   [26]
RP   VARIANTS AH5 PHE-53 DEL AND ASN-373.
RX   PubMed=19793597; DOI=10.1016/j.metabol.2009.07.024;
RA   Katsumata N., Ogawa E., Fujiwara I., Fujikura K.;
RT   "Novel CYP17A1 mutation in a Japanese patient with combined 17alpha-
RT   hydroxylase/17,20-lyase deficiency.";
RL   Metabolism 59:275-278(2010).
RN   [27]
RP   VARIANT AH5 GLN-96.
RX   PubMed=24498484; DOI=10.5001/omj.2014.12;
RA   Mula-Abed W.A., Pambinezhuth F.B., Al-Kindi M.K., Al-Busaidi N.B.,
RA   Al-Muslahi H.N., Al-Lamki M.A.;
RT   "Congenital adrenal hyperplasia due to 17-alpha-hydoxylase/17,20-lyase
RT   deficiency presenting with hypertension and pseudohermaphroditism:
RT   first case report from Oman.";
RL   Oman Med. J. 29:55-59(2014).
RN   [28]
RP   VARIANTS AH5 GLU-174; LEU-373 AND LEU-406, AND CHARACTERIZATION OF
RP   VARIANT AH5 LEU-406.
RX   PubMed=24140098; DOI=10.1016/j.metabol.2013.08.015;
RA   Kim Y.M., Kang M., Choi J.H., Lee B.H., Kim G.H., Ohn J.H., Kim S.Y.,
RA   Park M.S., Yoo H.W.;
RT   "A review of the literature on common CYP17A1 mutations in adults with
RT   17-hydroxylase/17,20-lyase deficiency, a case series of such mutations
RT   among Koreans and functional characteristics of a novel mutation.";
RL   Metabolism 63:42-49(2014).
RN   [29]
RP   VARIANT AH5 ARG-121, AND CHARACTERIZATION OF VARIANT AH5 ARG-121.
RX   PubMed=25650406; DOI=10.1530/EJE-14-0834;
RA   Rubtsov P., Nizhnik A., Dedov I.I., Kalinchenko N., Petrov V.,
RA   Orekhova A., Spirin P., Prassolov V., Tiulpakov A.;
RT   "Partial deficiency of 17alpha-hydroxylase/17,20-lyase caused by a
RT   novel missense mutation in the canonical cytochrome heme-interacting
RT   motif.";
RL   Eur. J. Endocrinol. 172:K19-25(2015).
CC   -!- FUNCTION: Conversion of pregnenolone and progesterone to their 17-
CC       alpha-hydroxylated products and subsequently to
CC       dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both
CC       the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved
CC       in sexual development during fetal life and at puberty.
CC       {ECO:0000269|PubMed:22266943}.
CC   -!- CATALYTIC ACTIVITY: A C(21)-steroid + [reduced NADPH--hemoprotein
CC       reductase] + O(2) = a 17-alpha-hydroxy-C(21)-steroid + [oxidized
CC       NADPH--hemoprotein reductase] + H(2)O.
CC       {ECO:0000269|PubMed:22266943}.
CC   -!- CATALYTIC ACTIVITY: 17-alpha-hydroxyprogesterone + [reduced
CC       NADPH--hemoprotein reductase] + O(2) = androstenedione + acetate +
CC       [oxidized NADPH--hemoprotein reductase] + H(2)O.
CC       {ECO:0000269|PubMed:22266943}.
CC   -!- CATALYTIC ACTIVITY: 17-alpha-hydroxypregnenolone + [reduced
CC       NADPH--hemoprotein reductase] + O(2) = 3-beta-hydroxyandrost-5-en-
CC       17-one + acetate + [oxidized NADPH--hemoprotein reductase] +
CC       H(2)O. {ECO:0000269|PubMed:22266943}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:22266943};
CC   -!- ENZYME REGULATION: Regulated predominantly by intracellular cAMP
CC       levels.
CC   -!- PATHWAY: Lipid metabolism; steroid biosynthesis.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000305}.
CC   -!- PTM: Phosphorylation is necessary for 17,20-lyase, but not for 17-
CC       alpha-hydroxylase activity. {ECO:0000269|PubMed:10720067}.
CC   -!- DISEASE: Adrenal hyperplasia 5 (AH5) [MIM:202110]: A form of
CC       congenital adrenal hyperplasia, a common recessive disease due to
CC       defective synthesis of cortisol. Congenital adrenal hyperplasia is
CC       characterized by androgen excess leading to ambiguous genitalia in
CC       affected females, rapid somatic growth during childhood in both
CC       sexes with premature closure of the epiphyses and short adult
CC       stature. Four clinical types: 'salt wasting' (SW, the most severe
CC       type), 'simple virilizing' (SV, less severely affected patients),
CC       with normal aldosterone biosynthesis, 'non-classic form' or late-
CC       onset (NC or LOAH) and 'cryptic' (asymptomatic).
CC       {ECO:0000269|PubMed:10720067, ECO:0000269|PubMed:11549685,
CC       ECO:0000269|PubMed:11836339, ECO:0000269|PubMed:12466376,
CC       ECO:0000269|PubMed:14671162, ECO:0000269|PubMed:1515452,
CC       ECO:0000269|PubMed:1714904, ECO:0000269|PubMed:1740503,
CC       ECO:0000269|PubMed:19793597, ECO:0000269|PubMed:24140098,
CC       ECO:0000269|PubMed:24498484, ECO:0000269|PubMed:25650406,
CC       ECO:0000269|PubMed:2808364, ECO:0000269|PubMed:8027220,
CC       ECO:0000269|PubMed:8245018, ECO:0000269|PubMed:8345056,
CC       ECO:0000269|PubMed:8396144, ECO:0000269|PubMed:8550762,
CC       ECO:0000269|Ref.20}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=CYP17A1";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M14564; AAA52151.1; -; mRNA.
DR   EMBL; M19489; AAA36405.1; -; Genomic_DNA.
DR   EMBL; M63871; AAA59984.1; -; Genomic_DNA.
DR   EMBL; M31153; AAA52140.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M31146; AAA52140.1; JOINED; Genomic_DNA.
DR   EMBL; M31147; AAA52140.1; JOINED; Genomic_DNA.
DR   EMBL; M31148; AAA52140.1; JOINED; Genomic_DNA.
DR   EMBL; M31149; AAA52140.1; JOINED; Genomic_DNA.
DR   EMBL; M31150; AAA52140.1; JOINED; Genomic_DNA.
DR   EMBL; M31151; AAA52140.1; JOINED; Genomic_DNA.
DR   EMBL; M31152; AAA52140.1; JOINED; Genomic_DNA.
DR   EMBL; BT020000; AAV38803.1; -; mRNA.
DR   EMBL; AL358790; CAI52498.1; -; Genomic_DNA.
DR   EMBL; BC062997; AAH62997.1; -; mRNA.
DR   EMBL; BC063388; AAH63388.1; -; mRNA.
DR   CCDS; CCDS7541.1; -.
DR   PIR; A40921; A26366.
DR   RefSeq; NP_000093.1; NM_000102.3.
DR   UniGene; Hs.438016; -.
DR   PDB; 2C17; Model; -; A=48-501.
DR   PDB; 3RUK; X-ray; 2.60 A; A/B/C/D=24-508.
DR   PDB; 3SWZ; X-ray; 2.40 A; A/B/C/D=24-508.
DR   PDB; 4NKV; X-ray; 2.65 A; A/B/C/D=24-508.
DR   PDB; 4NKW; X-ray; 2.50 A; A/B/C/D=24-508.
DR   PDB; 4NKX; X-ray; 2.79 A; A/B/C/D=24-508.
DR   PDB; 4NKY; X-ray; 2.55 A; A/B/C/D=24-508.
DR   PDB; 4NKZ; X-ray; 3.00 A; A/B/C/D=24-508.
DR   PDB; 5IRQ; X-ray; 2.20 A; A/B/C/D=24-508.
DR   PDB; 5IRV; X-ray; 3.10 A; A/B/C/D=24-508.
DR   PDBsum; 2C17; -.
DR   PDBsum; 3RUK; -.
DR   PDBsum; 3SWZ; -.
DR   PDBsum; 4NKV; -.
DR   PDBsum; 4NKW; -.
DR   PDBsum; 4NKX; -.
DR   PDBsum; 4NKY; -.
DR   PDBsum; 4NKZ; -.
DR   PDBsum; 5IRQ; -.
DR   PDBsum; 5IRV; -.
DR   ProteinModelPortal; P05093; -.
DR   SMR; P05093; -.
DR   BioGrid; 107958; 14.
DR   IntAct; P05093; 13.
DR   STRING; 9606.ENSP00000358903; -.
DR   BindingDB; P05093; -.
DR   ChEMBL; CHEMBL3522; -.
DR   DrugBank; DB05812; Abiraterone.
DR   DrugBank; DB04630; Aldosterone.
DR   DrugBank; DB01424; Aminophenazone.
DR   DrugBank; DB01234; Dexamethasone.
DR   DrugBank; DB02901; Dihydrotestosterone.
DR   DrugBank; DB01233; Metoclopramide.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB00396; Progesterone.
DR   GuidetoPHARMACOLOGY; 1361; -.
DR   SwissLipids; SLP:000001611; -.
DR   iPTMnet; P05093; -.
DR   PhosphoSitePlus; P05093; -.
DR   BioMuta; CYP17A1; -.
DR   DMDM; 117283; -.
DR   PaxDb; P05093; -.
DR   PeptideAtlas; P05093; -.
DR   PRIDE; P05093; -.
DR   DNASU; 1586; -.
DR   Ensembl; ENST00000369887; ENSP00000358903; ENSG00000148795.
DR   GeneID; 1586; -.
DR   KEGG; hsa:1586; -.
DR   CTD; 1586; -.
DR   DisGeNET; 1586; -.
DR   GeneCards; CYP17A1; -.
DR   HGNC; HGNC:2593; CYP17A1.
DR   HPA; HPA048533; -.
DR   MalaCards; CYP17A1; -.
DR   MIM; 202110; phenotype.
DR   MIM; 609300; gene.
DR   neXtProt; NX_P05093; -.
DR   OpenTargets; ENSG00000148795; -.
DR   Orphanet; 90796; 46,XY disorder of sex development due to isolated 17,20 lyase deficiency.
DR   Orphanet; 90793; Congenital adrenal hyperplasia due to 17-alpha-hydroxylase deficiency.
DR   PharmGKB; PA27090; -.
DR   eggNOG; KOG0156; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000118992; -.
DR   HOGENOM; HOG000036991; -.
DR   HOVERGEN; HBG106944; -.
DR   InParanoid; P05093; -.
DR   KO; K00512; -.
DR   OMA; LFLIMAW; -.
DR   OrthoDB; EOG091G0BT8; -.
DR   PhylomeDB; P05093; -.
DR   TreeFam; TF105095; -.
DR   BioCyc; MetaCyc:HS07560-MONOMER; -.
DR   BRENDA; 1.14.99.9; 2681.
DR   Reactome; R-HSA-193048; Androgen biosynthesis.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   SABIO-RK; P05093; -.
DR   SIGNOR; P05093; -.
DR   UniPathway; UPA00062; -.
DR   ChiTaRS; CYP17A1; human.
DR   GeneWiki; CYP17A1; -.
DR   GenomeRNAi; 1586; -.
DR   PRO; PR:P05093; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000148795; -.
DR   CleanEx; HS_CYP17A1; -.
DR   ExpressionAtlas; P05093; baseline and differential.
DR   Genevisible; P05093; HS.
DR   GO; GO:0030424; C:axon; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; NAS:ProtInc.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0047442; F:17-alpha-hydroxyprogesterone aldolase activity; IMP:UniProtKB.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0019825; F:oxygen binding; TAS:ProtInc.
DR   GO; GO:0004508; F:steroid 17-alpha-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0006702; P:androgen biosynthetic process; TAS:Reactome.
DR   GO; GO:0006704; P:glucocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0042446; P:hormone biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0042448; P:progesterone metabolic process; IDA:UniProtKB.
DR   GO; GO:0007548; P:sex differentiation; TAS:ProtInc.
DR   GO; GO:0006694; P:steroid biosynthetic process; TAS:ProtInc.
DR   GO; GO:0008202; P:steroid metabolic process; IDA:UniProtKB.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002401; Cyt_P450_E_grp-I.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00463; EP450I.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Congenital adrenal hyperplasia;
KW   Disease mutation; Heme; Iron; Lyase; Membrane; Metal-binding;
KW   Monooxygenase; Oxidoreductase; Phosphoprotein; Polymorphism;
KW   Reference proteome; Steroidogenesis.
FT   CHAIN         1    508       Steroid 17-alpha-hydroxylase/17,20 lyase.
FT                                /FTId=PRO_0000051931.
FT   METAL       442    442       Iron (heme axial ligand).
FT   VARIANT      22     22       C -> W (in dbSNP:rs762563).
FT                                /FTId=VAR_011755.
FT   VARIANT      35     35       P -> L (in AH5; 38% 17alpha-hydroxylase
FT                                activity and 33% 17,20-lyase activity).
FT                                {ECO:0000269|PubMed:10720067}.
FT                                /FTId=VAR_022745.
FT   VARIANT      53     53       Missing (in AH5; 10% 17alpha-hydroxylase
FT                                activity and 13% 17,20-lyase activity).
FT                                {ECO:0000269|PubMed:10720067,
FT                                ECO:0000269|PubMed:19793597,
FT                                ECO:0000269|PubMed:2808364}.
FT                                /FTId=VAR_001270.
FT   VARIANT      64     64       Y -> S (in AH5).
FT                                {ECO:0000269|PubMed:8396144}.
FT                                /FTId=VAR_001271.
FT   VARIANT      93     93       F -> C (in AH5; dbSNP:rs104894146).
FT                                {ECO:0000269|PubMed:11836339}.
FT                                /FTId=VAR_013147.
FT   VARIANT      96     96       R -> Q (in AH5; dbSNP:rs104894153).
FT                                {ECO:0000269|PubMed:24498484}.
FT                                /FTId=VAR_073043.
FT   VARIANT      96     96       R -> W (in AH5; 25% of both 17alpha-
FT                                hydroxylase and 17,20-lyase activities;
FT                                dbSNP:rs104894138).
FT                                {ECO:0000269|PubMed:10720067,
FT                                ECO:0000269|PubMed:14671162,
FT                                ECO:0000269|PubMed:8550762}.
FT                                /FTId=VAR_022746.
FT   VARIANT     106    106       S -> P (in AH5; dbSNP:rs104894135).
FT                                {ECO:0000269|PubMed:1714904}.
FT                                /FTId=VAR_001272.
FT   VARIANT     112    112       I -> II (in AH5).
FT                                {ECO:0000269|PubMed:8396144}.
FT                                /FTId=VAR_001273.
FT   VARIANT     114    114       F -> V (in AH5; dbSNP:rs104894147).
FT                                {ECO:0000269|PubMed:12466376}.
FT                                /FTId=VAR_022747.
FT   VARIANT     116    116       D -> V (in AH5; dbSNP:rs104894148).
FT                                {ECO:0000269|PubMed:12466376}.
FT                                /FTId=VAR_022748.
FT   VARIANT     121    121       W -> R (in AH5; partial loss of
FT                                activity). {ECO:0000269|PubMed:25650406}.
FT                                /FTId=VAR_073044.
FT   VARIANT     174    174       A -> E (in AH5).
FT                                {ECO:0000269|PubMed:24140098}.
FT                                /FTId=VAR_073045.
FT   VARIANT     177    177       N -> D (in AH5; 10% 17alpha-hydroxylase
FT                                and 17,20-lyase activities).
FT                                {ECO:0000269|PubMed:10720067}.
FT                                /FTId=VAR_022749.
FT   VARIANT     329    329       Y -> D (in AH5; dbSNP:rs104894144).
FT                                {ECO:0000269|PubMed:14671162}.
FT                                /FTId=VAR_022750.
FT   VARIANT     330    330       Missing (in AH5; complete loss of both
FT                                17alpha-hydroxylase and 17,20-lyase
FT                                activities).
FT                                {ECO:0000269|PubMed:10720067}.
FT                                /FTId=VAR_022751.
FT   VARIANT     342    342       P -> T (in AH5; dbSNP:rs104894137).
FT                                {ECO:0000269|PubMed:1740503}.
FT                                /FTId=VAR_001274.
FT   VARIANT     347    347       R -> C (in AH5; dbSNP:rs104894149).
FT                                {ECO:0000269|PubMed:12466376}.
FT                                /FTId=VAR_022752.
FT   VARIANT     347    347       R -> H (in AH5; selectively ablates
FT                                17,20-lyase activity, while preserving
FT                                most 17alpha-hydroxylase activity;
FT                                dbSNP:rs61754278).
FT                                {ECO:0000269|PubMed:11549685,
FT                                ECO:0000269|PubMed:12466376,
FT                                ECO:0000269|Ref.20}.
FT                                /FTId=VAR_001275.
FT   VARIANT     358    358       R -> Q (in AH5; selectively ablates
FT                                17,20-lyase activity, while preserving
FT                                most 17alpha-hydroxylase activity;
FT                                dbSNP:rs104894139).
FT                                {ECO:0000269|PubMed:11549685,
FT                                ECO:0000269|Ref.20}.
FT                                /FTId=VAR_001276.
FT   VARIANT     362    362       R -> C (in AH5; dbSNP:rs104894142).
FT                                {ECO:0000269|PubMed:14671162}.
FT                                /FTId=VAR_022753.
FT   VARIANT     373    373       H -> L (in AH5; dbSNP:rs760695410).
FT                                {ECO:0000269|PubMed:24140098,
FT                                ECO:0000269|PubMed:8245018}.
FT                                /FTId=VAR_001277.
FT   VARIANT     373    373       H -> N (in AH5).
FT                                {ECO:0000269|PubMed:19793597}.
FT                                /FTId=VAR_073046.
FT   VARIANT     406    406       W -> L (in AH5; complete loss of both
FT                                17alpha-hydroxylase and 17,20-lyase
FT                                activities).
FT                                {ECO:0000269|PubMed:24140098}.
FT                                /FTId=VAR_073047.
FT   VARIANT     406    406       W -> R (in AH5; dbSNP:rs104894143).
FT                                {ECO:0000269|PubMed:14671162}.
FT                                /FTId=VAR_022754.
FT   VARIANT     417    417       F -> C (in AH5; ablates both 17,20-lyase
FT                                activity and 17alpha-hydroxylase
FT                                activity; loss of heme-binding and loss
FT                                of phosphorylation; dbSNP:rs104894140).
FT                                {ECO:0000269|PubMed:10720067,
FT                                ECO:0000269|PubMed:11549685}.
FT                                /FTId=VAR_022755.
FT   VARIANT     428    428       P -> L (in AH5; dbSNP:rs104894145).
FT                                {ECO:0000269|PubMed:14671162}.
FT                                /FTId=VAR_022756.
FT   VARIANT     440    440       R -> H (in AH5; dbSNP:rs777638364).
FT                                {ECO:0000269|PubMed:8027220}.
FT                                /FTId=VAR_001278.
FT   VARIANT     487    489       Missing (in AH5).
FT                                {ECO:0000269|PubMed:8345056}.
FT                                /FTId=VAR_001279.
FT   VARIANT     496    496       R -> C (in AH5).
FT                                {ECO:0000269|PubMed:1515452}.
FT                                /FTId=VAR_001280.
FT   VARIANT     496    496       R -> H (in AH5; 30% 17alpha-hydroxylase
FT                                activity and 29% 17,20-lyase activity;
FT                                dbSNP:rs763398879).
FT                                {ECO:0000269|PubMed:10720067}.
FT                                /FTId=VAR_022757.
FT   STRAND       36     42       {ECO:0000244|PDB:3SWZ}.
FT   HELIX        49     55       {ECO:0000244|PDB:3SWZ}.
FT   HELIX        57     60       {ECO:0000244|PDB:3SWZ}.
FT   STRAND       62     68       {ECO:0000244|PDB:3SWZ}.
FT   STRAND       71     76       {ECO:0000244|PDB:3SWZ}.
FT   HELIX        79     86       {ECO:0000244|PDB:3SWZ}.
FT   TURN         87     93       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       100    105       {ECO:0000244|PDB:3SWZ}.
FT   TURN        106    109       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      111    115       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       119    131       {ECO:0000244|PDB:3SWZ}.
FT   TURN        132    135       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      136    138       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       142    159       {ECO:0000244|PDB:3SWZ}.
FT   TURN        160    162       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      163    165       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       168    184       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       194    209       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      211    214       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       220    222       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       228    250       {ECO:0000244|PDB:3SWZ}.
FT   TURN        251    253       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       262    271       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       285    287       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       289    320       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       322    335       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      338    340       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       344    348       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       351    363       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      376    381       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      384    386       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      391    394       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       396    401       {ECO:0000244|PDB:3SWZ}.
FT   TURN        403    405       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      406    408       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       414    417       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      422    425       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       438    440       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       445    462       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      463    466       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      479    485       {ECO:0000244|PDB:3SWZ}.
FT   STRAND      491    495       {ECO:0000244|PDB:3SWZ}.
FT   HELIX       497    501       {ECO:0000244|PDB:3SWZ}.
SQ   SEQUENCE   508 AA;  57371 MW;  E5454E9E18F96B0E CRC64;
     MWELVALLLL TLAYLFWPKR RCPGAKYPKS LLSLPLVGSL PFLPRHGHMH NNFFKLQKKY
     GPIYSVRMGT KTTVIVGHHQ LAKEVLIKKG KDFSGRPQMA TLDIASNNRK GIAFADSGAH
     WQLHRRLAMA TFALFKDGDQ KLEKIICQEI STLCDMLATH NGQSIDISFP VFVAVTNVIS
     LICFNTSYKN GDPELNVIQN YNEGIIDNLS KDSLVDLVPW LKIFPNKTLE KLKSHVKIRN
     DLLNKILENY KEKFRSDSIT NMLDTLMQAK MNSDNGNAGP DQDSELLSDN HILTTIGDIF
     GAGVETTTSV VKWTLAFLLH NPQVKKKLYE EIDQNVGFSR TPTISDRNRL LLLEATIREV
     LRLRPVAPML IPHKANVDSS IGEFAVDKGT EVIINLWALH HNEKEWHQPD QFMPERFLNP
     AGTQLISPSV SYLPFGAGPR SCIGEILARQ ELFLIMAWLL QRFDLEVPDD GQLPSLEGIP
     KVVFLIDSFK VKIKVRQAWR EAQAEGST
//
